Though insulin is associated with the risk of hypoglycemia and weight gain, the addition of vildagliptin or vildagliptin and metformin improved glycemic control with an associated insulin-sparing effect in patients with T2DM. The gene discussed is INS; the disease is Hypoglycemia.